Neuroscience
| 6 min read
New software and hardware tools that collect data while a person types can detect fine motor impairment — a possible sign of neurodegeneration.
| 4 min read
An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.
| 3 min read
Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.
| 4 min read
Trontinemab clears amyloid faster and more safely than previous drugs for Alzheimer’s disease. Will it convince skeptical regulators?
| 3 min read
Blood tests can’t diagnose Alzheimer’s disease yet, but one is already approved and more are on the way.
| 4 min read
Short-acting psychedelics like bretisilocin could offer rapid, lasting relief for patients with major depressive disorder.
| 3 min read
Oral GLP-1 data, srRNA therapies, and decentralized CAR T led drug discovery this week.
| 4 min read
Boston meeting brought scientists and industry leaders together to discuss disease mechanisms, advanced models, and research funding pressures.
| 3 min read
COPD breakthroughs, billion-dollar biotech bets, brain-computer trials, and a historic push for women’s health led the news this week.
| 2 min read
The therapy crosses the blood-brain barrier after peripheral injection and delivers behavioral improvements that last up to seven days.
| 4 min read
FDA rejections and safety concerns, a once-monthly HIV PrEP pill, developments in neuroscience drug development, and more led the news this week.
| 3 min read
Boosting UBA5 gene production normalized neuronal activity in the first organoid model of the developmental and epileptic encephalopathy.
